Stem Cell Transplantation |
From the Centre de Recherches du Service de Santé des Armées, La Tronche, France (MD, J-FM; AP, FH); Unité de Thérapie cellulaire, Groupe Hospitalier Pitié Salpêtrière Paris, France (FN); Centre Hospitalo-Universitaire Grenoble, France (J-PZ, CL)
Correspondence: Michel Drouet, Experimental Radiohematology Unit, Centre de Recherches du Service de Santé des Armées, 24 Avenue des Maquis du Grésivaudan, 38702, La Tronche, France. E-mail: micheldrouet{at}crssa.net
|
|
|---|
) Cynomolgus macaques were given autologous hepatic mononuclear cells (HMNC) isolated from a liver lobe by perfusion and digestion with 0.1% collagenase. Two monkeys were given intramedullary injections of HMNC (18.6x106/kg, 20.4x106/kg) and two others were co-transplanted with HMNC (14.35x106/kg, 96.5x106/kg) and bone marrow mesenchymal stem cells (0.42x106/kg, 1.16x106/kg). All monkeys exhibited a transient neutrophil recovery from day 22 for 10 days, but failed to produce platelets and remained transfusion-dependent. In conclusion, adult liver stem cells from a monkey model show a low level of in vivo hematopoietic potential, suggesting ex vivo manipulation will be required before clinical use of such cells.
Key words: plasticity, liver, non-human primate, irradiation, mesenchymal stem cells.
In recent years, grafting hematopoietic stem cells from solid organs has emerged as a promising concept in autologous transplantation settings in onco-hematology. The rationale is that contamination by malignant stem cells could be avoided provided that multipotent stem cells residing outside bone marrow are preserved from carcinogenic mutation(s) as a consequence of early embryonic divergence. Liver could be a valuable candidate in this context because hematopoiesis and hepatic development share common stages.1 The hematopoietic potential of adult liver cells has been described by a few teams.2–6 However, there is still controversy about the origin of the stem cells responsible and the underlying mechanisms. The hematopoietic activity of adult liver cells could be related to circulating hematopoietic stem cells, which reside in the liver but that have come from bone marrow (BM). Con sistent with this hypothesis, Uchida et al.5 reported that mouse liver contains a spectrum of hematopoietic cells that are phenotypically and functionally similar to those of marrow; Kotton et al. suggested that the hematopoietic activity is restricted to CD45-positive side population cells.6 Alternatively, hematopoietic activity of adult liver could be explained by adult stem cell plasticity, a concept that has been introduced to explain the capacity of resident tissue stem cells to recapitulate the ontogeny of other tissues. 7 Unfortunately, as a general concern, initial enthusiastic descriptions of plasticity in mice have not been confirmed in large animal models. Thus, there is still a need to characterize human liver stem cells and to compare their functionality with that of BM hematopoietic stem cells (HSC). Our team has suggested a non-hematopoietic origin for liver stem cells with in vitro hematopoietic potential.8 The present study was aimed at clarifying some of these points. Hepatic mononuclear cells (HMNC) were first transplanted alone. Then, based on studies from our group and others,9,10 we tested the putative enhancing effect of co-grafting liver cells and bone marrow mesenchymal stem cells (MSC).
|
|
|---|
Liver cells
After left hepatic lobectomy under general anesthesia (Imalgene, Mérial, Lyon, France; 10 mg/kg intramuscularly), liver lobes were first depleted of blood cells by perfusion with HEPES (10 mM/L) solution (Life Technologies, Cergy-Pontoise, France) then liver cells were isolated by perfusion and digestion with 0.1% collagenase A (Roche Diagnostics, Meylan, France) diluted in HEPES with 0.075% CaCl2. All liver cells, including HMNC, were then cryopreserved. Viable HMNC were enumerated according to morphological criteria, which allow easy separation from hepatocytes. For flow cytometric analysis, HMNC were labeled using phycoerythrin (PE) directly conjugated mouse anti-CD34 (clone 563, BD Biosciences, Le Pont-de-Claix France) and fluorescein isothiocyanate (FITC) directly conjugated mouse anti-CD45 (clone D058-1283, specifically raised against non-human primate CD45 antigen, BD Biosciences) monoclonal antibodies. Hematopoietic clonogenicity was assayed using a short-term assay in semi-solid medium (Methocult GF H4435; Stem Cell Technologies, Meylan, France) supplemented with 25 ng/mL of bone morphogenic protein 4 (BMP-4, R & D systems, Abingdon, UK).
Reverse-transcription and real time quantitative polymerase chain reaction (qRT-PCR) analysis
Messenger RNA was isolated from CD34+ and CD34– cells after cell sorting (FACS Vantage option DiVA, BD Biosciences). qRT-PCR was performed as previously described.11 Quantification was carried out using geometric averaging of three internal control genes (ACTB, GAPDH, HPRT) as reported by Vandesompele et al.12
Mesenchymal stem cells
As monkey MSC cannot be routinely cultured due to spuma virus infection and retrovirus-free human MSC can be detected after transplantation in non-human primates, we used a xenograft model.10 Human MSC layers were pre-established by culturing BM cells from a healthy donor (after informed consent),13 then cryopreserved in liquid nitrogen until use.
Transplantation study
After a 2-month rest, the anesthetized monkeys were globally exposed to a total dose of 2x5 Gy with a 60Co
radiation source (dose rate of 15 cGy/min); using frontal then dorsal irradiation on two consecutive days. This dose schedule is lethal without HSC transplantation.10 HMNC±MSC were infused directly into the humerus on the day after the second fraction of irradiation. Two animals were given an autologous HMNC graft alone (monkeys S024 and 3537), two were co-grafted with autologous HMNC±MSC (monkeys 4157 and Z836) and two were left ungrafted as controls (monkeys 3648D and 10090). Short-term reconstitution was defined as the time to achieve granulocyte recovery (absolute neutrophil count [ANC] >1x109/L) and platelet recovery (PLT >20x109/L).
|
|
|---|
![]() View larger version (14K): [in a new window] [Download PPT slide] |
Figure 1. Characterization of liver mononuclear cells. (A) Flow cytometric analysis of CD45 and CD34 antigen expression: [1] CD34neg CD45pos liver-resident lymphocytes, [2] CD34pos CD45neg liver stem cells; (B–D) Reverse-transcription and real time quantitative PCR analysis: CD45 (B), WASP (C) and GATA-4 (D). The level of mRNA expression was quantified using geometric averaging of three internal control genes as a reference. For each gene, mRNA expression level was normalized using total liver cells as a standard which was arbitrarily attributed a value of one.
|
|
View this table: [in a new window] [Download PPT slide] |
Table 1. Graft cell content and hematopoietic parameters of the grafted monkeys.
|
HMNC and MSC co-transplantation
The neutrophil recovery of monkeys 4157 and Z836, co-grafted with HMNC and MSC, was similar to that of monkeys S024 and 3537 (Table 1 and Figure 2). Neutrophil recovery occurred from day 22 and day 25 and was shorter (4 and 8 days, respectively). Monkey 4157 appeared to exhibit platelet recovery on day 20 before dying from non-hematologic toxicity on day 25.
![]() View larger version (20K): [in a new window] [Download PPT slide] |
Figure 2. Hematopoietic parameters over 49 days of monkey Z836 co-grafted with autologous hepatic mononuclear cells and mesenchymal stem cells. Platelets (PLT), absolute neutrophil count (ANC), lymphocytes (Ly), monocytes (Mono). PLT peaks indicate blood cell transfusion.
|
In fact, a definitive comparison between liver and BM stem cells was not possible because of the difference in phenotype. An average of about two total colony-forming units (CFU) could be enumerated in 105 HMNC so that graft cell contents (about 0.1x104/kg CFU) were far under the cell threshold capable of ensuring stable hematopoietic recovery using BM-derived HSPC (7.9 and 8.6x104/kg CFU).18 Clearly, the liver stem cell pool must be amplified to get a clinical benefit, for example by co-culturing stem cells on accessory/stromal cells.9,10 Here no significant improvement in hematopoietic recovery was observed when the HMNC were co-grafted with MSC although monkey 4157 appeared to exhibit platelet recovery on day 20. Other strategies need to be explored. Indeed, so far HSC residing in non-hematopoietic organs have shown only a low potential in primate models.19
All authors: conception and design, analysis and interpretation of data, drafting the article and final approval of the version to be published. We thank Philippe Garrigou and Jean-François Franetich for helpful collaboration, Nancy Grenier, Maud Fontenaud, Hervé Chaussard and Stephane Baugé for technical assistance.
The authors reported no potential conflicts of interest.
Funding: Supported by grants from Association pour la Recherche sur le Cancer and Délégation Générale pour lArmement.
Received for publication September 8, 2006. Accepted for publication December 6, 2006.
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||